3 registrations that name black Pepper as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 3 registrations
Status
Phase
2US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 3 registrations
RecruitingNCT06063486
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
Phase 2
University of Southern California
About 30 people
Started Mar 1, 2024
In plain words A Phase 2 study of black Pepper in people 18 and older, run by University of Southern California. It plans to enroll about 30 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Clonal Cytopenia of Undetermined Significance; Essential Thrombocythemia; Myelodysplastic Syndrome; Myelofibrosis; Polycythemia Vera.
Age >= 18
Eastern Cooperative Oncology Group (ECOG) =< 2
Ability to understand and willingness to sign a written informed consent
Diagnosis of polycythemia vera (PV), essential thrombocytosis (ET) or myelofibrosis (MF) per World Health Organization (WHO) 2016 diagnostic criteria
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement; Piperine Extract (Standardized); Placebo Administration; Questionnaire Administration
Registered summary
This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic syndrome (LR-MDS), and myeloproliferative neoplasms (MPN). Chronic inflammation drives disease development and contributes to symptoms experienced by patients with CCUS, LR-MDS, and MPN. Curcumin has been shown to have anti-inflammatory and anti-cancer properties and has been studied in various chronic illnesses and hematologic diseases.
Where, as registered
2 US sites in 1 state.
RecruitingNCT06080841
Curcumin Supplementation in Cervical Cancer
No phase
National Institute of Cancerología
About 30 people
Started Apr 19, 2023
In plain words A study of black Pepper in female participants 18 and older, run by National Institute of Cancerología. It plans to enroll about 30 people at 1 site, none in the US.
Understanding the nature of the study and giving a written consent report.
Women > 18 years old.
ECOG performance status: 0-2.
Be willing and able to comply with scheduled visits, treatment plans, and laboratory tests.
9 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Curcumin; Curcumin + Piperine
Registered summary
Brief Summary. The goal of this pilot study is to learn about the effect of curcumin supplementation in locally advanced cervical cancer patients. The main questions it aims to answer are: * Does curcumin supplementation increase the levels of p53 and apoptosis in tumor cells from cervical cancer patients? * At which dose of curcumin supplementation is the broader effect observed for p53 expression and apoptosis in tumor cells from cervical cancer patients? * Are all doses safe for supplementation? Participants will be asked to take curcumin tablets throughout their cancer treatment. The full summary is on the listing.
Where, as registered
No US site; Mexico (1).
Not yet recruitingNCT07753018
Effects of Curcumin-Piperine Supplementation in Fibromyalgia
Phase 2
Ain Shams University
About 80 people
Starts Aug 1, 2026 (estimated)
In plain words A Phase 2 study of black Pepper in female participants 18 and older, run by Ain Shams University. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Fibromyalgia (FM).
Adult women aged ≥18 years.
Patients with confirmed diagnosis of fibromyalgia, according to 2022 ACR Fibromyalgia criteria.
The exclusion criteria are on the listing.
What it tests, as registered
Curcumin - Piperine; Placebo
Registered summary
The goal of this clinical trail is to evaluate the effectiveness and safety of curcumin-piperine supplementation in patients with fibromyalgia over 3 months compared to placebo. Participants will: Be randomly assigned to receive either curcumin and piperine supplements or a placebo. Attend scheduled clinic visits for clinical assessments and blood sample collection. Complete study questionnaires before and after treatment time frame. The full summary is on the listing.